| 81 | 0 | 215 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 建立那屈肝素钙药物利用评价(DUE)标准,评价屈肝素钙的临床应用合理性,为临床合理使用屈肝素钙提供参考。方法 成立合理用药评价小组,基于循证医学/药学证据建立那屈肝素钙DUE标准,利用属性层次模型对那屈肝素钙的临床使用进行合理性评价。结果 那屈肝素钙围手术期预防性使用不合理问题较多,内科科室那屈肝素钙使用合理率高于外科科室。那屈肝素钙使用不合理问题主要为用法用量不合理(281例,占82.40%)、未开展实验室监测(178例,占52.20%)和用药时机不合理(156例,占45.75%)。病历得分为(73.16±9.91)分,评价等级为合格和良好的病例分别占比57.77%和34.90%。结论 建立的那屈肝素钙DUE标准具有科学性,可用于那屈肝素钙的临床合理性评价。该院那屈肝素钙的临床使用存在一些不合理问题,使用那屈肝素钙的病历评价等级主要为合格和良好,优秀和不合格的病例较少。临床应重视那屈肝素钙使用中存在的不合理问题。
Abstract:AIM To establish the drug use evaluation(DUE) criteria of nadroparin calcium, and evaluate its ratonality of clinical application, providing a reference for rational clinical use. METHODS A rational drug use evaluation team was set up to establish the DUE criteria of nadroparin calcium based on the evidence-based medical/pharmacy evidence. The attribute hierarchical model(AHM) method was used to evaluate the rationality of clinical use of nadroparin calcium. RESULTS During the perioperative period, there were many unreasonable prophylactic uses of nadroparin calcium in the medical records of this evaluation, with the rational rate of use being higher in the internal medicine department compared to surgical department. The primary issues with the unreasonable clinical use of nadroparin calcium were improper use and dosage(281 cases, 82.40%), lack of laboratory monitoring(178 cases, 52.20%), and inappropriate timing of medication administration(156 cases, 45.75%). The medical record score(MRS) was(73.16 ± 9.91) points, with cases rated as qualified and good accounting for 57.77% and 34.90%, respectively. CONCLUSION The DUE criteria of nadroparin calcium established are scientific and feasible to evaluate the rationality of nadroparin calcium for clinical use. There are certain concerns regarding the clinical use of nadroparin calcium in the hospital. The evaluation grades for medical records concerning nadroparin calcium are mostly categorized as qualified or good, with very few cases rated as excellent or unqualified. Clinicians need to pay attention to the unreasonable use of nadroparin calcium.
[1]国家卫生健康委加速康复外科专家委员会骨科专家组,中国研究型医院学会骨科加速康复专业委员会,中国康复技术转化及促进会骨科加速康复专业委员会.骨科大手术加速康复围手术期静脉血栓栓塞症防治专家共识[J].中华骨与关节外科杂志,2022,15(10):754.
[2]重庆市医院协会药事管理专业委员会,钱妍,赵春景.抗凝药物审方规则专家共识[J].中国药房,2023,34(24):2951.
[3]姚莉,姜倩,崔梦茹,等.急性肺血栓栓塞症患者低分子肝素抗凝治疗中抗Xa因子活性的影响因素分析[J].中国临床药学杂志,2024,33(5):339.
[4]王鹏鸽,胡芝芝,张丹丹,等.不同类型肝素对维持性血液透析患者骨密度的影响[J].临床肾脏病杂志,2017,17(7):391.
[5]HAO C,SUN M J,WANG H M,et al.Low molecular weight heparins and their clinical applications[J].Prog Mol Biol Transl Sci,2019,163:21.
[6]俞秀恒,郭艺楠,赵语.基于属性层次模型和加权TOPSIS法的低分子肝素注射液药物利用评价标准建立与应用[J].中国药业,2024,33(8):106.
[7]王芳芳,陈锦珊,陈国权,等.骨科那屈肝素药物利用评价标准的建立与应用[J].中国医院用药评价与分析,2023,23(3):325.
[8]中华医学会骨科学分会创伤骨科学组,中华医学会骨科学分会外固定与肢体重建学组,中国医师协会骨科医师分会创伤专家工作委员会,等.中国创伤骨科患者围手术期静脉血栓栓塞症预防指南(2021)[J].中华创伤骨科杂志,2021,23(3):185.
[9]中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组.肺血栓栓塞症诊治与预防指南[J].中华医学杂志,2018,98(14):1060.
[10]FALANGA A,AY C,DI NISIO M,et al.Venous thromboembolism in cancer patients:ESMO Clinical Practice Guideline[J].Ann Oncol,2023,34(5):452.
[11]中华医学会妇产科学分会产科学组.妊娠期及产褥期静脉血栓栓塞症预防和诊治专家共识[J].中华妇产科杂志,2021,56(4):236.
[12]中华医学会围产医学分会.产科抗磷脂综合征诊断与处理专家共识[J].中华围产医学杂志,2020,23(8):517.
[13]低分子肝素防治自然流产中国专家共识编写组.低分子肝素防治自然流产中国专家共识[J].中华生殖与避孕杂志,2018,38(9):701.
[14]徐蕾,张伟霞,许倍铭,等.那屈肝素临床应用药学专家意见[J].上海医药,2022,43(21):12.
[15]宋佳伟,王媛媛,陈慧娟,等.属性层次模型在帕洛诺司琼药物利用评价中的应用[J].中国临床药学杂志,2022,31(7):523.
[16]李素琼,班立丽.国内外药物利用评价研究综述[J].中国医院用药评价与分析,2021,21(7):893.
[17]程乾生.属性层次模型AHM:一种新的无结构决策方法[J].北京大学学报(自然科学版),1998,34(1):10.
[18]周武,曹发奇,曾睿寅,等.创伤骨科患者围术期下肢静脉血栓形成诊断及防治专家共识(2022年)[J].中华创伤杂志,2022,38(1):23.
[19]GODIER A,FONTANA P,MOTTE S,et al.Management of antiplatelet therapy in patients undergoing elective invasive procedures:proposals from the French Working Group on perioperative hemostasis(GIHP)and the French Study Group on thrombosis and hemostasis(GFHT).In collaboration with the French Society for Anesthesia and Intensive Care(SFAR)[J].Arch Cardiovasc Dis,2018,111(3):210.
[20]VAN REIN N,BIEDERMANN J S,VAN DER MEER F J M,et al.Major bleeding risks of different low-molecular-weight heparin agents:a cohort study in 12 934 patients treated for acute venous thrombosis[J].J Thromb Haemost,2017,15(7):1386.
[21]中国医师协会急诊医师分会,国家卫健委能力建设与继续教育中心急诊学专家委员会,中国医疗保健国际交流促进会急诊急救分会.急性冠脉综合征急诊快速诊治指南(2019)[J].中国急救医学,2019,39(4):301.
[22]DAVIDSON B L,VERHEIJEN S,LENSING A W A,et al.Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin[J].JAMA Intern Med,2014,174(6):947.
[23]中国医师协会心血管内科医师分会血栓防治专业委员会,《中华医学杂志》编辑委员会.肝素诱导的血小板减少症中国专家共识(2017)[J].中华医学杂志,2018,98(6):408.
[24]宋佳伟,王媛媛,陈慧娟,等.多模式干预对帕瑞昔布临床应用合理性的影响[J].中国临床药学杂志,2021,30(6):433.
基本信息:
DOI:10.19577/j.1007-4406.2026.01.006
中图分类号:R969.3
引用信息:
[1]陈慧娟,刘丽,孟冰冰,等.基于属性层次模型评价那屈肝素钙的临床使用合理性[J].中国临床药学杂志,2026,35(01):34-40.DOI:10.19577/j.1007-4406.2026.01.006.
基金信息:
亳州市卫生健康委科研重点项目(编号bzwj2023b004)
2026-01-25
2026-01-25